ODTX · CIK 0001882782
What Odyssey Therapeutics, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for ODTX. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- BIOSECURE Act / China CRO-CMO restrictionsmedium
Legislation such as the BIOSECURE Act could restrict long-term commercial agreements with certain CMOs; combined with US-China trade tensions, this threatens its reliance on Chinese CROs/CMOs and could raise costs.
“Additionally, legislation and regulations, such as the BIOSECURE Act, could restrict our ability to enter into long-term commercial agreements with certain CMOs.”
Supplier concentration
- fabless; reliant on third-party CMOs for drug candidatesmedium
Owns no manufacturing; relies entirely on third-party contract manufacturing organizations (CMOs) to produce its drug candidates under FDA cGMP for clinical trials.
“We do not currently own or operate any manufacturing facilities. We rely on third-party contract manufacturing organizations, or CMOs, to produce our drug candidates in accordance with the U.S. Food and Drug Administration’s, or the FDA, current good manufacturing practices, or cGMPs, for use in our clinical trials.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Revenue from the Pfizer MTA is recognized over the estimated performance of the R&D services using the time-elapsed input method which the Company believes best depicts the transfer of control to Pfizer.”
Cited →“Revenue from the J&J Agreement is recognized over the estimated performance of the initial research and development services using the cost incurred input method, which the Company believes best depicts the transfer of control to J&J.”
Cited →Terray Therapeutics
“No upfront payments were made upon the execution of the Terray Agreement and there have not been any payments made or received from the profit and loss share arrangement under the Terray Agreement as of December 31, 2025.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch